CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (223)	6/17/1999 5:20:00 PM
From: Vector1	Read Replies (2) of 666

Story 4725 =DJ Coulter Pharma Up -4: Advisory Committee Is Catalyst Vector's Toth, who rates Coulter at buy, said it is "highly likely" Bexxar will be approved this year. By meeting the June 30 deadline Coulter assures that the FDA's decision will come this year, making it a catalyst for the stock in 1999 as opposed to 2000. "The real catalyst isn't the FDA's final approval, but if the Biological Response Modifiers Committee recommends approval," Toth said. The committee advises the FDA and is scheduled to meet in the fall. - Gregg Henglein; 201-938-5175 (END) DOW JONES NEWS 06-17-99 04:40 PM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next